TIAA Trust National Association Increases Position in Gilead Sciences, Inc. $GILD

TIAA Trust National Association raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,548 shares of the biopharmaceutical company’s stock after purchasing an additional 5,050 shares during the period. TIAA Trust National Association’s holdings in Gilead Sciences were worth $3,627,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Paulson Wealth Management Inc. increased its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. increased its position in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the last quarter. Alpha Cubed Investments LLC increased its position in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Personal CFO Solutions LLC increased its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Scotiabank increased their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Citigroup upped their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Leerink Partners lowered their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $156.93.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive Phase 3 results for a once-weekly HIV regimen using islatravir and lenacapavir, a potential advance that could strengthen Gilead’s already important HIV franchise and support long-term revenue growth. Article Title
• Positive Sentiment: Analysts and recent commentary pointed to momentum in Gilead’s HIV portfolio, including strength in Biktarvy and Descovy, as well as improving expectations for Yeztugo and other late-stage pipeline assets. Article Title
• Positive Sentiment: Gilead said topline Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis showed significantly more patients reached key treatment goals, which could broaden the company’s pipeline and add another growth driver. Article Title
• Neutral Sentiment: Gilead presented at the Goldman Sachs Global Healthcare Conference, which likely reinforced management’s pipeline and growth narrative but did not appear to include a major new catalyst. Article Title
• Negative Sentiment: Gilead and Merck also ended a Phase 3 lung cancer study after Trodelvy plus KEYTRUDA failed to deliver a statistically significant improvement, renewing concern around Gilead’s oncology strategy. Article Title
• Negative Sentiment: Biopharma coverage noted that the Trodelvy setback creates risk for one of Gilead’s key cancer programs, even as HIV progress remains the bigger driver for the stock. Article Title

Gilead Sciences Trading Down 3.2%

Shares of Gilead Sciences stock opened at $121.48 on Thursday. The company has a fifty day simple moving average of $133.73 and a 200-day simple moving average of $134.34. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a market cap of $150.83 billion, a price-to-earnings ratio of 16.55 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $9,047,570 in the last 90 days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.